A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)
Subjects who have completed study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 µg in study 4975-MN-203 if they meet the inclusion/exclusion criteria.
Morton's Neuroma
DRUG: CNTX-4975
Evaluate the safety and tolerability of repeat injections of CNTX-4975 through assessment of incidence, intensity, relationship and seriousness of treatment-emergent adverse events, over the course of 1 year.|Evaluate the safety and tolerability of repeat injections of CNTX-4975 through treatment-emergent changes in vital signs and laboratory tests, over the course of 1 year.
To evaluate the analgesic efficacy of repeat doses of CNTX-4975 by change in NPRS., over the course of 1 year.|To evaluate the analgesic efficacy of repeat doses of CNTX-4975 by change in Patient Global Impression of Change, over the course of 1 year.
Subjects who have completed study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 µg in study 4975-MN-203 if they meet the inclusion/exclusion criteria.